Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of oral ivosidenib in adults with locally advanced or metastatic conventional chondrosarcoma that has an IDH1 gene mutation. This Phase 3, international, multicenter, double-blind study compares ivosidenib to a placebo in participants who have measurable disease that has progressed or recurred and who have received up to two prior systemic treatments. The trial focuses on progression-free survival as the primary outcome, especially in Grades 1 and 2 chondrosarcoma participants. Participants will be randomly assigned to receive either ivosidenib 500 mg tablets or matching placebo tablets taken orally once daily. Treatment continues until disease progression confirmed by a blinded independent central review, unacceptable side effects, pregnancy, death, withdrawal, loss to follow-up, or study end. Those on placebo who experience disease progression and meet criteria may cross over to receive ivosidenib. The estimated average treatment duration is about two years. During the study, participants will undergo regular imaging scans to assess tumor response and progression according to RECIST criteria. Researchers will monitor survival outcomes up to five years and evaluate safety through adverse event reporting. Quality of life questionnaires and blood tests to measure drug and biomarker levels will be collected. The total participation duration may extend up to five years, including treatment and follow-up assessments.